Australia's Argenica jumps on ethics approval to start stroke treatment trial

Argenica Therapeutics

07/09/2022 06:05

** Shares of Australia's Argenica Therapeutics Ltd  AGN.AX 
rise as much as 2.1% to A$0.49, their biggest intraday pct gain
since Aug 25
    ** The biotechnology co says it received ethics approval to
start Phase 1 clinical trial of ARG-007 in healthy participants
 urn:newsml:reuters.com:*:nASX4gW56G
    ** ARG-007 is a neuroprotective peptide drug to be used in
treatment of strokes - co
    ** Says process to recruit volunteers into trial will now
start, with dosing of first cohort of volunteers expected in
October
    ** About 340,000 shares change hands, vs the 30-day average
volume of 73,000 shares
    ** Shares down 42.5% YTD, as of last close 
    

 (Reporting by Nausheen Thusoo)
 ((Nausheen.Thusoo@thomsonreuters.com;))